Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review ...

DBV Technologies is presenting new positive Phase 3 data for its VIASKIN Peanut Patch, including results in children with additional atopic conditions. The company has also started a Phase 2 trial in ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today provided an update on the Biologics License Application (BLA) ...

DBV (DBVT) stock analysis \| sector rotation trends, earnings catalysts, trading volume. DBV Technologies (DBVT) shares rose 5.29% to close at $17.41, with trading volume notably a ...

DBV to pursue an Accelerated Approval pathway for toddlers ages 1 - 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers ...

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The study is evaluating the efficacy and safety of the VIASKIN ® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages 6 through 12 months with peanut allergy First ...

Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq ...